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CTN Transplant Trials vs. Investigator Initiated Transplant Trials
U of M Investigator
Initiated Trials
DM hours
prior to
enrollment (1) Accrual
Date
1st patient
enrolled
Screening
Hours
Total Screen
hrs/ patient
DM Hr
After 1st
Enrollmment (2)
Total DM
Hrs/patient
Investigated Initiated Transplant
Conditioning (elderly AML)
28 12 05/18/2007 22 1.83 451 37.58
Investigator Initiated Transplant
Conditioning (CloBu4)
23 15 10/09/2007 30 2.00 305 20.33
Ph II Trial of Adjuvant Cellular
Immunotherapy for High-Risk
Hematologic Malignancy After
Reduced Intensity Allo SCT
Unk (3) 26 07/08/2003 97 3.73 1898 73.00
The addition of Etanercept to
Standard GVHD prophy in
Patients undergoing a full
intensity Unrelated donor
HSCT for the prevention
for Transplant Related
Complications
Unk (3) 71 12/06/2004 110 1.55 1770 24.93
Average
Screening
Hours/patient
2.28 Average DM
hours/patient
after 1st
enrollment
38.96
CTN Trials DM Hours
Prior to 1st
Enrollment (1)
Accrual Date 1st
Patient
Enrolled
Screening Hours Total Screen
Hrs/pt
DM Hr
after 1st
Enrollment (2)
Total DM
Hrs/patient
CTN 0501 71 4 02/03/2007 21 5.25 540 135
CTN 0401 28 11 12/06/2006 92 8.36 665 60.45
CTN 0402 150 10 01/04/2007 59 5.90 465 46.50
CTN 0201 31 12 11/22/2006 124 10.33 475 39.58
Average
Screening
Hours/patient
7.46 Average DM
hours/patient
after 1st
enrollment
70.38
(1) From ‘‘first effort logged’’ to
day prior to first enrollment
(2) Hours from 1st patient
enrolled through 5/30/2008
(3) First patient enrolled prior
to initiation of time tracker
96 Poster Session-Ipatient, likely due to more comprehensive testing to evaluate eligi-
bility, and 3) Differences in the amount of data collected may
account for some portion of the different expenditures in time
per patient. While potential savings are unlikely to be as high as
the total cost differential, at our center alone the total additional
expense for patients enrolled to the four CTN trials is almost
$33,000 for the effort reporting period examined. If CTN were
to write future protocols in a manner that allowed sites to follow
their institutional CPG whenever possible, there could be a signifi-
cant savings of time and money.263
SPECIALIZATION: FOCUSED EFFORT PRODUCES INCREASED ACCESS TO
BLOOD/MARROW TRANSPLANT PROGRAM
McClain, K.A. Baylor University Medical Center, Dallas, TX
Purpose: Due to the rising cost of healthcare and current eco-
nomic environment, many employers have made significant changes
to the healthcare coverage offered to their employees over the last
three to five years. Anticipating an increase in the number of patients
referred to our transplant program with benefit design limitations or
exclusions, as well as increased out-of-network referrals, a dedicated
Transplant Benefit Specialist (TBS) was hired to attempt to resolve
these issues on a case-by-case basis. Prior to implementing this staff-
ing change, only 11% of out-of-network blood/marrow transplant
patients were able to stay at Baylor University Medical Center via
a negotiated individual patient agreement between the payor, hospi-
tal and/or transplant physicians.
Method:TheTBS acts as the liaison between and among the hos-
pital, transplant physicians, payor, patient and employer ensuring
that all parties have all pertinent information in order to make aneducated decision on completing a one-time individual patient
agreement. The TBS advocates on behalf of the patient by providing
the following categories of information to the payor: clinical situa-
tion of the patient, BUMC’s outcomes for the particular transplant
type, rates/language available. In situations where a benefit design
maximum applies or a service is excluded from a policy, the TBS
assists the patient in submitting an exception request to the payor
or employer. The exception request typically includes a letter from
the consulting physician outlining the patient’s clinical situation
and suggested treatment protocol, a letter from the patient, as well
as a formal exception request letter from the TBS providing perti-
nent outcomes.
Results:The percent of converted out-of-network blood/marrow
cases increased from 11% in FY 05 to 62% in FY 07. The ability to
trend benefit design issues by payor has also resulted in changes to
the standard benefit offerings of major payors that previously were
outliers in our market.
Conclusion: A focused effort on this subset of patients dramati-
cally increased their access to our blood/marrow transplant program.
The data collected by the TBS has been a valuable tool used to edu-
cate payors and employers about their benefit design selection and its
impact on actual patient lives.264
DOCUMENTING DISEASE RESPONSE IN TRANSPLANT PATIENTS FOR THE
PURPOSE OF ACCURATE REPORTING TO THE CIBMTR
Thomas, T.K. St. Louis Children’s Hospital, Washington University,
St. Louis, MO
Background: Extracting accurate and relevant details regarding
disease response at fixed time-points as required by the Center for
Poster Session-I 97International Blood and Marrow Transplantation (CIBMTR) data
forms is a necessary but time consuming process for research coordi-
nators, as timing and methods of follow up vary. CIBMTR data
forms that were completed retrospectively reflected differences in
disease assessment criteria and resulted in extensive review of past
documentation in medical records prior to reporting. Accurate
data submission often required teasing out fine details of clinical as-
sessment to distinguish between complete response, very good par-
tial response, stable disease, and no response, particularly in
patients with solid tumors and lymphoma. This is due in part, to
the continued presence of lesions whose significance was not explic-
itly addressed in the medical record but are often attributed to resid-
ual fibrosis or scar tissue. These issues often had to be resolved after
a
repeat review and discussion between data managers and treating
physicians.
Intervention: We created disease response forms for diseases
that required exact assessment and reporting. The forms were
based on CIBMTR criteria for response. These forms are then
used for documentation of disease at diagnosis, at any time of
disease status change, pre-transplant, and post-transplant accord-
ing to the CIBMTR form submission schedule. Data managers
completed the forms and presented them to treating physicians
for verification and signature. This signed document became
a source document which was placed in the patient’s medical
record.
Results:Wehave implemented disease response sheets for neuro-
blastoma, lymphoma, and juvenile myelomonocytic leukemia
(JMML), and intend to create the same for sarcomas and CNS
tumors. Our experience indicates that these forms improve data
accuracy, are efficient at data capture, and provide consistent
uniform documentation that conforms to disease response criteria
established and required by the CIBMTR.265
STREAMLINING SAE REPORTING FOR CTN TRIALS RESULTS IN SIGNIFI-
CANT TIME SAVINGS
Buck, T.A., James, P., Levine, J.E., Ramakrishnan, A. University of
Michigan Cancer Center, Ann Arbor, MI
Reporting serious adverse events (SAEs) for Blood and Marrow
Transplant Clinical Trials Network (CTN) studies generally
requires detailed information to be entered into the EMMES
database so that a medical director can review it and determine
whether the event is expected or unexpected. When SAE report-
ing requires reporting concomitant medications, lengthy amounts
of time are spent identifying and recording these medications. If
the event is determined to be expected, a report is not required
and the data manager is requested to delete the information that
was entered. The University of Michigan (U of M) set out to
find an alternative that would save the time required to enter
information that may ultimately be deleted. During a routine
CTN audit in January 2008, U of M data managers worked
with auditors to develop a solution centered around who deter-
mines that an event is expected. For all SAEs requiring an initial
report to CTN, a report must also be filed with the U of M
Institutional Review Board (IRB). Because reports submitted to
the IRB require the local principal investigator to make a deter-
mination whether an event is expected or unexpected, it seemed
redundant to have CTN also perform the same evaluation. With
a new function in the EMMES database that allows sites to
upload supporting documents for SAE reporting, a solution was
reached whereby the SAE reports submitted to the U of M
IRB could also be uploaded into the EMMES system for the
medical director’s review. Thus the requirement to enter detailed
information that might ultimately have to be deleted was elimi-
nated. The University of Michigan Clinical Trials Office utilizes
a time and effort tracker tool that records and categorizes data
management time spent on study related tasks. This tool was
used to evaluate the amount of time spent reporting SAEs during
2007 (prior to the CTN audit) and for the 7 months in 2008
after implementing the new reporting process for 5 CTN trials
open during the two time periods. In order to compare acrosstime periods of different length, average SAE reporting time
per event was compared. We found time savings for each study,
ranging from 0.22 to 1.89 hours per SAE, with an average sav-
ings of approximately one hour per SAE. When multiplied by
the 114 SAEs reported on these studies alone, time savings
approach 3 weeks of data management time. If this system was
extended across the entire network the time and money savings
could be substantial.
Time Requirements for SAE Reporting
# SAE # SAEStudyreports
Jan-Dec
2007Total
reporting
hours
Hours
per SAEreports
Feb-Aug
2008Total
reporting
hoursHours
per
SAESavings
in
HoursCTN 0201 10 21 2.1 16 19.3 1.21 0.89
CTN 0501 11 35.5 3.2 10 13.4 1.34 1.89
CTN 0302 20 31 1.55 11 13 1.18 0.37
CTN 0401 8 24.3 3.04 3 3.5 1.17 1.87
CTN 0402 11 29.5 2.68 14 34.5 2.46 0.22
Total 60 144.6 54 83.72
Average 2.51 1.47 1.04266
ESTABLISHING A DATA MANAGEMENT AT HSCT UNIT IN THE UNIVER-
SITY OF CAMPINAS
Miranda, E.C.M., Vigorito, A.C., De Souza, C.A. University of Campi-
nas, Campinas, SP, Brazil
The University of Campinas (UNICAMP) created a department
of Hematopoietic Stem Cell Transplantation (HSCT) attached in
the Hematology and Hemotherapy Service on September, 1993.
Our department has a multidisciplinary team, physicians, psychiat-
ric, psychologist, dentist, nurses, social assistant, therapeutic, biolo-
gist, pharmacist, fellows, data manager and biostatistics. Until
August 2008 it was done 837 procedures in a total of 682 patients,
443 (65%) allogeneic HSCT and 239 (35%) autologous HSCT.
The most diseases submitted to the HSCT are leukemia, myelodys-
plastic disorders, aplastic anemia, Non-Hodgkin and Hodgkin
Lymphomas andMultiple Myeloma. Our center it was denominated
as a Research Center by CIBMTR. Last November the CIBMTR
informed that 644 patients and 744 transplants were registered,
however, we have more 42 registered patients until last August. A
routine had to be established for not losing the control. First step
was to recognize the flowing procedure of each department in order
to know where information is and/or who can help to answer the
doubts. Secondly, a database, with few but essential variables, guides
us how to conduct a daily routine. It means to identify how many
patients have a full report or a Transplant Essential Data (TED)
forms due. This simple database must be updated every day, mainly
because if a patient has an event, the team has to checkwhether or not
the information has to be sent to the CIBMTR. There is a constant
relationship between the team and data center in order to maintain
the updated routine. A good tool was to develop specific forms to
the allied health professionals. Hence, our data center produces
and gives some support in different HSCT studies, resulting in
several published papers and titles of Master and PhD.267
MANAGING OUR FORMS BEFORE THEY MANAGE US!
Rainey, K.S. Barnes-Jewish Hospital, Saint Louis, MO
Problem: By law mandatory sets of data must be reported to
SCTOD for pre-transplant, 100 days post transplant, six months
post, one year post and yearly thereafter. The staff at SitemanCancer
Center looked at current processes and found the data needed to
complete these forms existed in over 20 information systems and
gathering of data was all manual. No standard for completion of
data forms existed, nor any process to assure forms were completed
in proper succession. Operations Analysts had to switch back and
